SAB Biotherapeutics Warrant
SABSW
9 hedge funds and large institutions have $22.3K invested in SAB Biotherapeutics Warrant in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
5.19% less ownership
Funds ownership: 11.91% → 6.72% (-5.2%)
18% less funds holding
Funds holding: 11 → 9 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
57% less capital invested
Capital invested by funds: $52.1K → $22.3K (-$29.8K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
+$11.6K |
| 2 |
CS
Clear Street
New York
|
+$7 |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
-$20.2K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$11.8K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$9 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HWM
1
HB Wealth Management
Atlanta,
Georgia
| $11.2K | +$11.6K | +310,000 | New |
|
2
Morgan Stanley
New York
| $5.27K | – | – | – |
|
|
YCM
3
Yakira Capital Management
Westport,
Connecticut
| $3.91K | – | – | – |
|
4
Walleye Capital
New York
| $837 | – | – | – |
|
5
Walleye Trading
New York
| $558 | – | – | – |
|
|
WAM
6
Wolverine Asset Management
Chicago,
Illinois
| $558 | +$7 | +200 | +1% |
|
|
NA
7
NewEdge Advisors
New Orleans,
Louisiana
| $39 | – | – | – |
|
|
CS
8
Clear Street
New York
| $7 | +$7 | +200 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $2 | – | – | – |
|
|
LP
10
LMR Partners
London,
United Kingdom
| – | -$20.2K | -539,588 | Closed |
|
|
SCM
11
Shaolin Capital Management
Miami,
Florida
| – | -$11.8K | -249,143 | Closed |
|
|
12
Bank of America
Charlotte,
North Carolina
| – | -$9 | -200 | Closed |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$3 | -56 | Closed |
|
SABSW Hedge Fund Activity: Q3 2024 in Review
9 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q3 2024, worth a combined $22.3K — down 57% from $52.1K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SABSW and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was HB Wealth Management, opening a new position worth an estimated $11.6K. The largest seller was LMR Partners, exiting entirely with an estimated $20.2K sold.
- 9 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q3 2024, down from 11 in Q2 2024.
- Funds reported $22.3K of SAB Biotherapeutics Warrant stock for Q3 2024, down 57% quarter-over-quarter.
- 2 funds opened new SAB Biotherapeutics Warrant positions in Q3 2024 and 4 closed out, a net change of -2 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q3 2024 was HB Wealth Management, an estimated $11.6K added.
- The largest SAB Biotherapeutics Warrant seller in Q3 2024 was LMR Partners, an estimated $20.2K sold.
Based on aggregated 13F filings for Q3 2024.